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Nuclear receptors are important to maintain the tissue homeostasis. Each receptor is
tightly controlled and under a very complicated balance. In this review, we summarize
the current findings regarding the nuclear receptor TR4 and its role in prostate cancer
(PCa) progression. In general, TR4 can inhibit the PCa carcinogenesis. However, when
PPARγ is knocked out, activation of TR4 can have an opposite effect to promote the PCa
carcinogenesis. Clinical data also indicates that higher TR4 expression is found in PCa
tissues with high Gleason scores compared to those tissues with low Gleason scores.
In vitro and in vivo studies show that TR4 can promote PCa progression. Mechanism
dissection indicates that TR4 inhibits PCa carcinogenesis through regulating the tumor
suppressor ATM to reduce DNA damages. On the other hand, in the absence of PPARγ,
TR4 tends to increase the stem cell population and epithelial–mesenchymal transition (EMT)
via regulating CCL2, Oct4, EZH2, and miRNA-373-3p expression that results in increased
PCa carcinogenesis. In opposition to PCa initiation, TR4 can increase PCa metastasis
via modulating the CCL2 signals. Finally, targeting TR4 enhances the chemotherapy and
radiation therapy sensitivity in PCa. Together, these data suggest TR4 is a key player to
control PCa progression, and targeting TR4 with small molecules may provide us a new
and better therapy to suppress PCa progression.
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introduction
The testicular nuclear receptor 4 (TR4) was first cloned in 1994, and was identified as one of critical nuclear 
receptors to maintain the physiological homeostasis (1). As a transcription factor, TR4 binds to the direct 
repeat sequence (AGGTCA with spacings of 0–6) to regulate its target genes transcription (2, 3). The upstream 
modulators including natural polyunsaturated fatty acids (PUFA) or synthetic  thiazolidinediones (TZD) can 
activate TR4 function (4, 5). Phosphorylation (6, 7) or acetylation (8) of TR4, on the other hand, will inhibit its 
activity. As a result, many physiological functions are maintained and regulated including metabolism, fertility, 
bone formation, and neural development in the whole body (7, 9–16). In this review, we will summarize the 
current findings of TR4 roles in prostate cancer (PCa) progression.
TR4 Role in PCa initiation
Both in vivo and in vitro studies indicated that TR4 acts as a caretaker tumor suppressor that suppresses 
PCa initiation through promoting DNA repair and maintaining genome integrity (17). In vivo mouse 
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data showed prostatic intraepithelial neoplasia (PIN) was found 
in prostates of old TR4 knockout (TR4-/-) mice, while their wild 
type TR4 (TR4+/+) littermates showed normal prostate histology. 
Furthermore, both PTEN+/- and TRAMP PCa mouse models 
showed one allele deletion of TR4 could accelerate the PCa initia-
tion. In the PTEN+/-/TR4+/- model, the mice not only form PIN 
as expected in PTEN+/-/TR4+/+ mice, but also form PCa tumors at 
15 months old that does not happen in the PTEN+/-/TR4+/+ mice 
(17). In the TRAMP mouse model, TR4+/-/TRAMP mice can form 
tumors or severe PIN as early as 24 weeks while the TR4+/+/TRAMP 
mice only form minor PIN. In summary, three mouse models all 
confirm that loss of TR4 will accelerate the PCa initiation.
In vitro data also support the in vivo findings showing that two 
normal prostate epithelial cell lines can be transformed more easily 
when TR4 is knocked-down by TR4-shRNA (17). Mechanistically, 
Lin et al. found the DNA repair gene ATM can be regulated by TR4 
at the transcription level. The two PCa mouse models and two cell 
lines showed ATM was reduced dramatically, with DNA damage 
increased, when TR4 is reduced by one allele deletion or knocked-
down by TR4-shRNA (17). Finally, the clinical data also revealed 
that ATM expression is highly correlated with TR4 expression in 
PCa tissues (17). Together, these findings suggest TR4 can prevent 
PCa initiation through maintaining DNA integrity.
PPARγ and TR4 interplay in PCa initiation
Lin et  al. analyzed Peroxisome Proliferator-Activated receptor 
gamma (PPARγ) gene deletion in 69 human PCa samples with 
fluorescent in situ hybridization (FISH) assays, and results showed 
9% of PCa samples have one allele PPARγ deletion. In contrast, 
there was no PPARγ deletion in their normal prostate compart-
ment (Fisher’s test, p = 0.0279), suggested the deletion of PPARγ 
may have some linkage to the PCa initiation (18).
Early reports found that TZDs, the agonists of PPARγ might be 
also able to activate TR4, suggesting a potential cross-talk might 
exist between these two nuclear receptors (5). It would be interest-
ing to see if TR4 might exert different effects in PCa cells with or 
without PPARγ deletion. Lin et al. assayed the cell proliferation 
in PPARγ naïve mPrE (mPrE+/+) versus PPARγ knockout mPrE 
prostate cells (mPrE-/-). The results showed knocking down TR4 
suppressed cell proliferation in mPrE-/- cells under carcinogen treat-
ment, which are opposite the results found in the mPrE+/+ cells (17). 
Next, they found overexpression of TR4 promoted cell proliferation 
in mPrE-/- cells under carcinogen treatment. Together, the in vitro 
results suggest TR4 has different functions in the presence or 
absence of PPARγ that can promote prostate epithelial cell growth.
Lin et al. then used different assays to test whether the status of 
PPARγ deletion may also influence TR4 effect on PCa initiation. 
Using cell transformation with colony formation assays, they 
found knocking-down TR4 suppressed, while overexpression of 
TR4 promoted PCa carcinogenesis in mPrE-/- cells, which is also 
opposite from the mPrE+/+ cells data (17). Together, results support 
the above findings that different TR4 effects on prostate epithelium 
cell proliferation and PCa initiation are dependent on the deletion 
status of PPARγ (17, 18).
Another approach that may be similar to deleting PPARγ is to 
apply an antagonist to suppress PPARγ activity. Lin et al. treated 
mPrE+/+ cells with PPARγ inhibitor GW9662 and assayed the cell 
growth by MTT assay. The results showed knocking down TR4 in 
mPrE+/+ cells treated with GW9662 suppressed cell proliferation, 
which is consistent with the mPrE-/- cell data above. Together, the 
results confirm the above conclusion that TR4 may exert different 
effects on prostate cell proliferation depending on the PPARγ status 
that either was deleted or suppressed by its antagonists (18).
To prove the above in vitro cell lines data in vivo, Lin et  al. 
applied a xenograft mouse model to test whether TR4 could also 
promote mPrE-/- tumor growth in vivo. TR4 was either overex-
pressed or knocked-down in mPrE-/- cells, and a total of 106 cells 
were then subcutaneously injected into the dorsal flank of the 
mice. The PCa mass in mice injected with overexpressed TR4 cells 
were much larger than those in the control group at 7 weeks. In 
contrast, at 14 weeks, much smaller PCa masses were seen in the 
mice injected with TR4 knocked-down cells. These in vivo results 
therefore confirmed the in vitro data showing overexpressing TR4 
could lead to PCa tumor growth in mPrE-/- cells xenografts (18).
The morphology showed that overexpressing TR4 increased 
prostate de-differentiation in mPrE-/- cells. In contrast, knocking-
down TR4 failed to show such prostate de-differentiation in 
mPrE-/- cells, suggesting TR4 might regulate PCa growth in the 
absence of PPARγ by mediating PCa to a more poorly differenti-
ated type of cancer. Molecular mechanism dissection found 
overexpressing TR4 in mPrE-/- cells enhanced the expression of 
CD44 and Scal1, but eliminated the expression of E-cadherin, 
indicating an epithelial–mesenchymal transition (EMT) in the 
stem cell-like population among PCa cells (18).
TZD effect on TR4 in PCa Progression
Thiazolidinediones (TZD) are potent anti-diabetic drugs that 
function through targeting PPARγ (19). An earlier report showed 
that TZD could also activate TR4 (5). Lin et al. found 9% of PCa 
patients have the TR4 gene deletion. It is important to test whether 
TZD treatment has different effects between tumors/cells with 
wild type TR4 versus TR4 deletion. They first applied TR4–shRNA 
to knock-down TR4 in PCa CWR22RV1 cells to mimic the TR4 
deletion and then treated with TZD. Interestingly, they found TZD 
treatment could promote CWR22RV1 cell growth significantly 
compared to vehicle control. In contrast, TZD showed no effect 
on CWR22RV1 cell growth compared to vehicle control when cells 
were transfected with scramble shRNA (20).
Lin et al. then applied the second growth assay, an anchorage 
independent assay also known as colony formation assay, to test 
TZD differential effects. As expected, TZD treatment could also 
dramatically increase colony formation in CWR22RV1 cells where 
TR4 is knocked down compared to vehicle control. In contrast, 
TZD treatment decreased colony formation on CWR22RV1 cells 
transfected with scramble shRNA compared to vehicle control. 
They also confirmed these different in  vitro phenotypes using 
another PCa cell line, C4-2, and obtained similar results (20). 
Together, the results suggest that TZD treatment may have different 
effects on PCa progression that depends on the TR4 expression 
status.
Lin et  al. were also interested to see if TZD treatment may 
have different effects on PCa metastasis, and therefore applied 
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the Boyden chamber migration/invasion assays to examine 
the CWR22RV1 metastatic ability. TZD treatment increased 
CWR22RV1_shTR4 migration significantly compared to vehicle 
control. In contrast, TZD treatment decreased CWR22RV1_scr 
migration compared to vehicle control. For the invasion assays, 
they pre-coated membranes between upper and bottom wells 
with matrigel to mimic in  vivo invasion, as the cancer cells 
need to invade into the extracellular matrix. TZD treatment 
increased CWR22RV1_shTR4 invasion significantly compared 
to vehicle control. In contrast, TZD treatment had no effect on 
CWR22RV1_scr invasion compared to vehicle control. They also 
confirmed these different in vitro phenotypes using C4-2 cells, 
and obtained similar results (20). Together, the results suggest that 
TZD treatment may also have different effects on PCa metastasis 
that depends on the TR4 expression status.
To confirm the in vitro finding in vivo, Lin et al. xenografted 
TZD treated CWR22RV1_scr and CWR22RV1_shTR4 cells 
into nude mice prostate. They sacrificed the mice at 4  weeks 
after inoculation and found the CWR22RV1_shTR4 group grew 
larger tumors than the CWR22RV1_scr group. Furthermore, 
they found CWR22RV1_shTR4 group had more metastasis than 
CWR22RV1_scr group (20). Together, the results conclude that 
TZD treatment has adverse effects on PCa progression in  vivo 
when TR4 is low, and suggests treating those diabetic PCa patients 
who lost one allele of TR4 with TZD may lead to PCa progression.
TZD Has Different effects on HRAS 
expression
Lin et al. then wanted to know what is downstream of TZD to 
induce PCa progression. They screened 35 metastasis-related 
genes and found HRAS mRNA increased in both PCa cell lines, 
CWR22RV1_shTR4 and C4-2_shTR4, treated with TZD, but 
decreased in the scramble controls treated with TZD. Furthermore, 
they confirmed TZD could increase HRAS promoter activity by 
luciferase-reporter assay when TR4 is knocked down (20). These 
findings fit the phenotypes showing TZD treatment has differential 
effects depending on the TR4 status.
HRAS Specific inhibitor interrupts TZD 
induced Cell Migration and invasion
After finding the potential candidate HRAS, Lin et  al. tried to 
inhibit HRAS by treating with the specific inhibitor farnesyl 
thiosalicylic acid (FTS). They treated the four sub-clones (scramble 
shRNA_DMSO, scramble shRNA_TZD, TR4 shRNA_DMSO, and 
TR4 shRNA_TZD) of CWR22RV1 and C4-2 cells with 50 μM 
FTS for 2 weeks. After treatment, they assayed the cell migration 
and invasion as described above. The results showed FTS could 
successfully interrupt TZD induced migration and invasion in 
both cell lines (20).
Conclusion of TR4, PPARγ, and TZD
The interaction between TR4 and PPARγ in PCa is more compli-
cated than we expected. In the absence of PPARγ, TR4 becomes 
an oncogene instead of a tumor suppressor gene. Reciprocally, 
in the absence of TR4, PPARγ becomes an oncogene instead of a 
tumor suppressor gene through TZD signaling. Recently, the two 
major TZD anti-diabetic drugs, Avandia (rosiglitazone) and Actos 
(pioglitazone), have been withdrawn or received warnings against 
use by the FDA, respectively. The major warning for Actos use is 
that long-term treatment may increase bladder cancer risk. Yang 
et al. found 38% of bladder cancer patients have a PPARγ gene 
amplification, which indicates the unbalance between TR4 and 
PPARγ plays an important role in both PCa and bladder cancer (21).
After screening 35 metastasis-related genes expression in PCa 
cell lines, Lin et  al. found TZD treatment can increase HRAS 
mRNA level only when TR4 is reduced. In contrast, TZD did not 
increase, but decreased HRAS mRNA level when TR4 is normal. 
Some reports have demonstrated HRAS is not only the oncogene 
for cancer initiation, but also can increase PCa metastasis (22, 23).
Together, the results of this study conclude that TR4 is a key 
regulator to prevent TZD from being oncogenic. Patients with 
TR4 deletion should be warned about taking TZD, or consider 
combining TZD treatment with FTS to eliminate the side effects.
TR4 Role in PCa Metastasis
Opposite to the PCa initiation, Ding et al. found TR4 could promote 
PCa metastasis (24). From the clinical PCa tissue staining results, 
Ding et al. showed higher expression of TR4 with high Gleason 
scores compared to the tissues with the low Gleason scores. In vitro 
assays showed that TR4 promoted PCa cells migration/invasion. 
Mechanism dissection using QPCR and ELISA found that the 
CCL2 signaling was increased, which may contribute to the media-
tion of TR4-promoted PCa cells migration/invasion. Chromatin 
immunoprecipitation (ChIP) and luciferase assays further 
confirmed TR4 modulation of CCL2 at the transcriptional level, 
and addition of the CCL2 receptor antagonist interrupted the TR4-
enhanced PCa cells migration/invasion. Finally, the orthotopic 
xenografted mice model confirmed that TR4 did enhance PCa 
metastasis, and the metastasis was alleviated when the mice were 
treated with the CCL2 receptor antagonist. Together, the clinical 
data as well as the in vitro and in vivo results revealed a positive 
TR4 role in PCa metastasis, which may function through CCL2 
signaling, and targeting the TR4-CCL2 axis may become a new 
therapeutic approach to battle PCa metastasis (24).
Another report revealed that TR4 might enhance PCa cells 
invasion via inhibition of the microRNA-373-3p (miR-373-3p) 
expression, and TR4-enhanced PCa cells invasion can be inter-
rupted by adding back the miR-373-3p (25). Mechanistically, 
they found that miR-373-3p functions through inhibition of the 
TGFβR2→p-Smad3 signals to inhibit the PCa cells invasion. The 
in vivo mouse model using orthotopic xenografts also confirmed 
that TR4 enhanced PCa metastasis is through the inhibition of miR-
373-3p. The data suggests that TR4 increases the PCa metastasis 
through the signaling of miR-373-3p, and using the TR4 antagonist, 
TR4-siRNA, or miR-373-3p may become a new potential thera-
peutic approach to better suppress PCa metastasis (25).
Moreover, Zhu et al. demonstrated that TR4 plays a positive 
role in PCa stem/progenitor (S/P) cell invasion (26), and targeting 
TR4 with shRNA significantly suppressed PCa S/P cell invasion 
both in vitro and in vivo. Mechanism dissection using ChIP and 
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luciferase assays found that TR4 transcriptionally regulates the 
oncogene EZH2. EZH2 may then regulate the expression of its 
downstream key metastasis-related genes including NOTCH1, 
TGFβ1, SLUG, and MMP9. Adding back EZH2 in the TR4–shRNA 
PCa cell lines can partially interrupt the TR4–shRNA suppression 
effect on PCa cells invasion. Together, these results suggest that 
EZH2 is another TR4 target that plays a critical role in the PCa 
S/P cell invasion (26).
TR4 Role in PCa Chemotherapy and 
Radiation Therapy
Zhu et al. demonstrated that TR4 plays a protective role against 
ionizing radiation (IR) in PCa cells, and targeting TR4 with shRNA 
enhances the IR sensitivity in PCa cells. Mechanism dissection 
found that targeting TR4 by shRNA enhanced miR-212-3p 
expression via de-methylation of the promoter region. Enhanced 
miR-212-3p then suppressed the expression of DNA damage/
repair related gene BRCA1 via binding to the BRCA1 mRNA 3′ 
un-translated region. Furthermore, the TR4–shRNA effect on 
enhancing PCa radiation sensitivity can be interrupted by add-
ing miR-212-3p inhibitor. Together, these results conclude that 
targeting TR4 can increase the IR sensitivity in PCa (26).
Prostate cancer S/P cells are known to have higher chem-
oresistance than non-S/P cells, but the underlying molecular 
mechanism remains unclear (27). Yang found the expression of 
TR4 is significantly higher in PCa S/P cells. Knocking down TR4 
in the PCa S/P cells with shRNA led to increased chemosensitivity 
to docetaxel and etoposide. Mechanism dissection showed that 
suppression of TR4 down-regulated the Oct4 expression, which, 
in turn, down-regulated the IL-1 receptor antagonist (IL1Ra) 
expression. To confirm this, Yang et al. performed the interrup-
tion assay by over-expression of Oct4 or adding back the IL1Ra 
recombinant, and found TR4–shRNA could no longer increase 
the chemosensitivity (28). Together, these studies suggest that 
targeting TR4 can alleviate the chemoresistance of PCa, therefore 
improve chemotherapy efficacy.
Conclusion
TR4, as a transcription factor, plays multiple functions in PCa 
through regulating a variety of downstream targets. In the PCa 
initiation, TR4 can prevent DNA damage by regulating the DNA 
repair genes ATM and BRCA1. When PPARγ is absent, TR4 tends 
to regulate the EMT with increased S/P population and therefore 
increases the PCa initiation. On the other hand, when TR4 is 
knocked-down by shRNA, the TR4 and PPARγ shared activator/
ligand, TZD, exclusively enhances PPARγ activity, which, in turn, 
increases PCa progression. When the PCa is developed, TR4 now 
becomes an activator to promote PCa cells invasion/metastasis. 
Increase of CCL2, decrease of miR-373-3p, and increase of EZH2 
by TR4 all contribute to the increased PCa invasion/metastasis. 
Finally, TR4 also contributes to the radiation therapy resistance and 
chemotherapy resistance. TR4 inhibits miR-212-3p that enhances 
BRCA1 expression in the PCa cell lines that contributes to the 
radiation resistance. TR4 can also increase Oct4, and therefore 
increase the S/P population that contributes to the chemoresist-
ance. Together, activation of TR4 may be beneficial to prevent 
the PCa initiation in patients in which the expression of PPARγ 
is normal, while inhibiting TR4 via siRNA may be beneficial to 
prevent the PCa metastasis (Figure 1).
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